newsfilter
← Latest News
GlobeNewswire·

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at